Immunovant Inc

Company Profile

Immunovant Inc had its IPO on 2019-06-21 under the ticker symbol IMVT.

The company operates in the Healthcare sector and Biotechnology industry. Immunovant Inc has a staff strength of 164 employees.

Stock update

Shares of Immunovant Inc opened at $22.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $21.95 - $23.15, and closed at $22.03.

This is a -2.31% slip from the previous day's closing price.

A total volume of 790,838 shares were traded at the close of the day’s session.

In the last one week, shares of Immunovant Inc have slipped by -8.17%.

Immunovant Inc's Key Ratios

Immunovant Inc has a market cap of $3.13 billion, indicating a price to book ratio of 4.7266 and a price to sales ratio of 0.

In the last 12-months Immunovant Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-233676000. The EBITDA ratio measures Immunovant Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Immunovant Inc’s operating margin was 0% while its return on assets stood at -36.1% with a return of equity of -66.41%.

In Q2, Immunovant Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Immunovant Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immunovant Inc’s profitability.

Immunovant Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -8.2242. Its price to sales ratio in the trailing 12-months stood at 0.

Immunovant Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$351.22 million

Total Liabilities

$51.36 million

Operating Cash Flow

$-45000.00

Capital Expenditure

$45000

Dividend Payout Ratio

0%

Immunovant Inc ended 2024 with $351.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $351.22 million while shareholder equity stood at $299.87 million.

Immunovant Inc ended 2024 with $0 in deferred long-term liabilities, $51.36 million in other current liabilities, 13000.00 in common stock, $-640284000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $329.96 million and cash and short-term investments were $329.96 million. The company’s total short-term debt was $919,000 while long-term debt stood at $0.

Immunovant Inc’s total current assets stands at $350.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $823000.00 compared to accounts payable of $26.46 million and inventory worth $0.

In 2024, Immunovant Inc's operating cash flow was $-45000.00 while its capital expenditure stood at $45000.

Comparatively, Immunovant Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$22.03

52-Week High

$25.128

52-Week Low

$4.26

Analyst Target Price

$29.77

Immunovant Inc stock is currently trading at $22.03 per share. It touched a 52-week high of $25.128 and a 52-week low of $25.128. Analysts tracking the stock have a 12-month average target price of $29.77.

Its 50-day moving average was $21.5 and 200-day moving average was $18.5 The short ratio stood at 3.44 indicating a short percent outstanding of 0%.

Around 5747.4% of the company’s stock are held by insiders while 4541% are held by institutions.